ClinicalTrials.gg
Active, not recruitingNCT04314687Updated Feb 25, 2026

Stem Cell and Conditioned Medium for Cerebral Palsy

A Phase 1/2 interventional study of Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium in Cerebral Palsy, sponsored by PT. Prodia Stem Cell Indonesia. Active, not recruiting at 1 site in Indonesia. Open to participants aged 6 Months to 3 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by PT. Prodia Stem Cell Indonesia · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
6 Months to 3 Years
Sex
All
01

Study summary

The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy.

Hypothesis: UCMSCs + CM therapy resulting in higher improvement in cognitive function, gross motor function and chemical factors than UCMSCs and standard therapy.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Allogeneic Mesenchymal Stem Cells
  • Umbilical Cord Mesenchymal Stem Cells
  • Intrathecal Injection
  • Cerebral Palsy
  • Conditioned Medium
03

In context

Cerebral Palsy

1,939 studies on the registry are indexed under Cerebral Palsy; 457 are open to participants now.

This study's planned enrollment of 78 is above the median of 34 across 1,432 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

PT. Prodia Stem Cell Indonesia is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as Cerebral palsy with total body involvement type
  • Age between 6 month - 3 years old
  • Parents requesting for cell therapy
  • The parents give sign in form do to examination, therapy, blood sampling collection and observation for their child

Exclusion criteria

Exclusion Criteria:

  • Head circumference less than -3 SD (more than 3 cm) Nellhaus standard
  • Have diagnosed meningitis and encephalitis
  • Have diagnosed congenital infection i.e. toxoplasmosis, rubella congenital, cytomegalovirus
  • Have diagnosed metabolic disorder, chromosome disorder, congenital malformation or neuroregeneratif disease
  • Progressive disorder
  • Regressive development disorder
  • Severe anatomical abnormalities in Brain MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Investigator)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    UCMSCs + CM

    UCMSCs + CM is administered via intrathecal injection

    Biological: Umbilical Cord Mesenchymal Stem Cells · Biological: Conditioned Medium

  • Experimental
    UCMSCs

    UCMSCs is administered via intrathecal injection

    Biological: Umbilical Cord Mesenchymal Stem Cells

  • Active comparator
    Standard Therapy

    Physiotherapy

    Other: Standard Therapy

Interventions

  • The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.

    Also known as: Allogeneic Mesenchymal Stem Cells

  • BiologicalConditioned Medium

    Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.

    Also known as: Umbilical Cord Mesenchymal Stem Cells derived Conditioned Medium

  • OtherStandard Therapy

    Standard therapy for cerebral palsy such as physiotherapy

    Also known as: Physiotheraphy

06

What researchers measure

Primary outcomes

  1. Gross Motor Function

    Gross Motor Function Classification System (GMFCS)

    Time frame: 3 month after stem cells

  2. Gross Motor Function

    Gross Motor Function Classification System (GMFCS)

    Time frame: 6 month after stem cells

  3. Gross Motor Function

    Gross Motor Function Measure (GMFM)

    Time frame: 3 month after stem cells

  4. Gross Motor Function

    Gross Motor Function Measure (GMFM)

    Time frame: 6 month after stem cells

  5. Cognitive Function

    Bayley Scales of Infant Development (BSID) version III

    Time frame: 3 month after stem cells

  6. Cognitive Function

    Bayley Scales of Infant Development (BSID) version III

    Time frame: 6 month after stem cells

Secondary outcomes

  1. Chemical Marker

    Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)

    Time frame: 3 month after stem cells

  2. Chemical Marker

    Insulin-like growth factor 1 (IGF-1); stromal derived factor-1α (SDF-1α); brain derived neurotrophic factors (BDNF), Vascular endothelial growth factor (VEGF),glial cell line-derived neutrophic factor (GDNF), fibroblast growth factor (FGF), Doublecortin (DCX)

    Time frame: 6 month after stem cells

07

Study locations

1 site
  • Indonesian National Brain Center
    Jakarta, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2021 (actual). Primary completion is estimated for Jul 2026, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2020
First posted
Mar 19, 2020
StartActual
Oct 13, 2021
Primary completionEst.
Jul 2026
CompletionEst.
Dec 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04314687
Lead sponsor
PT. Prodia Stem Cell Indonesia
Responsible party
Sponsor
First posted
Mar 19, 2020
Start date
Oct 13, 2021
Primary completion
Jul 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion